| Description | Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease. |
| In vivo | Valiglurax (0.3-30 mg/kg; po) reversed haloperidol-induced catalepsy (HIC) in rats[1]. |
| Synonyms | VU2957, VU 0652957, VU 2957, VU-0652957, VU0652957, VU-2957 |
| molecular weight | 329.28 |
| Molecular formula | C16H10F3N5 |
| CAS | 1976050-09-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 112.5 mg/mL (341.7 mM), Sonication is recommended. |
| References | 1. Panarese JD, et al. Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease. ACS Med Chem Lett. 2018 Oct 16;10(3):255-260. |